BIOMAT Database Logo BIOMAT Database Logo

Ipratropium bromide aerosol in chronic bronchitis. 1977

J Cummiskey, and P Keelan, and P Gray, and G A Cox

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009241 Ipratropium A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. N-Isopropylatropine,(endo,syn)-(+-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane,Atrovent,Ipratropium Bromide,Ipratropium Bromide Anhydrous,Ipratropium Bromide Monohydrate,Ipratropium Bromide, (endo,anti)-Isomer,Ipratropium Bromide, (exo,syn)-Isomer,Ipratropium Bromide, endo-Isomer,Itrop,Sch-1000,Sch-1178,N Isopropylatropine,Sch 1000,Sch 1178,Sch1000,Sch1178
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol

Related Publications

J Cummiskey, and P Keelan, and P Gray, and G A Cox
Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma.
February 1975, British medical journal,
J Cummiskey, and P Keelan, and P Gray, and G A Cox
The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis.
December 1978, Thorax,
J Cummiskey, and P Keelan, and P Gray, and G A Cox
Nebulised ipratropium bromide and salbutamol in chronic bronchitis.
January 1980, The British journal of clinical practice,
J Cummiskey, and P Keelan, and P Gray, and G A Cox
Effect of aerosol ipratropium bromide (SCH 1000) on sputum viscosity and volume in chronic bronchitis.
August 1977, British journal of clinical pharmacology,
J Cummiskey, and P Keelan, and P Gray, and G A Cox
Effect of ipratropium bromide (atrovent) inhalation in chronic bronchitis.
January 1985, The Indian journal of chest diseases & allied sciences,
J Cummiskey, and P Keelan, and P Gray, and G A Cox
Nebulized ipratropium bromide in ventilator-assisted patients with chronic bronchitis.
May 1994, Chest,
J Cummiskey, and P Keelan, and P Gray, and G A Cox
Bronchodilator action of the anticholinergic drug, ipratropium bromide (Sch 1000), as an aerosol in chronic bronchitis and asthma.
March 1977, Chest,
J Cummiskey, and P Keelan, and P Gray, and G A Cox
Direct labelling of ipratropium bromide aerosol and its deposition pattern in normal subjects and patients with chronic bronchitis.
June 1984, Thorax,
J Cummiskey, and P Keelan, and P Gray, and G A Cox
Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis.
July 1978, British journal of diseases of the chest,
J Cummiskey, and P Keelan, and P Gray, and G A Cox
Comparison of ipratropium bromide and fenoterol in asthma and chronic bronchitis.
December 1978, British journal of clinical pharmacology,
Copied contents to your clipboard!